Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJing WangWZWei Zhao

Discussion

Loading...

Member takes

Overview

Phase 2 trial showed golidocitinib plus CHOP achieves high response rates in patients with intestinal T-cell lymphoma, suggesting effective therapy.

Key Points

  • To evaluate the efficacy of golidocitinib combined with CHOP in treatment-naïve patients with MEITL.
  • Phase 2 multicenter, single-arm trial
  • Patients received golidocitinib plus CHOP regimen for 6 cycles
  • Assessments made through PET-CT based on Lugano criteria
  • 7 treatment-naïve MEITL patients enrolled
  • Complete response rate was 71.4% and overall response rate was 85.7%
  • Identified tumor microenvironment factors and JAK/STAT pathway involvement as response determinants

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1ebhttps://doi.org/10.1182/blood-2025-3649
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  2. 2Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025
  3. 3Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre2025
  4. 4Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis2025
  5. 5Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025